Renal Clear Cell CarcinomaNCT07332923
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
An observational study of Renal Clear Cell Carcinoma and HIF-2α, run by First Affiliated Hospital of Fujian Medical University at 1 site in China.
Trial summary
This project aims to conduct a multicenter retrospective study to collect clinical, CT imaging, and pathological data from patients. A comprehensive data management system will be established, and radiomic features will be extracted to integrate and analyze multicenter data. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Renal Clear Cell Carcinoma, HIF-2α, Radiomics
- How many people
- 500 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2024to 1 Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with histologically confirmed renal cell carcinoma
Who may be able to join
- Pathologically confirmed clear cell renal cell carcinoma (ccRCC)
- Availability of comprehensive clinical, pathological, and follow-up information
- Access to preoperative non-contrast and contrast-enhanced CT images through the PACS database
- Adequately preserved pathological slides for subsequent immunohistochemical (IHC) or tissue microarray analysis
- Minimum of one post-treatment follow-up with documented treatment response or efficacy evaluation
Who cannot join
- Patients considered ineligible for treatment owing to severe comorbid conditions or inability to undergo any therapeutic intervention
- Patients with concurrent malignancies, including prior treatment for other cancers or presence of untreated active malignancies
- Patients with inadequate CT image quality or missing imaging data
- Patients with missing or incomplete clinical, pathological, or follow-up information
Trial locations and contacts
1 site in 1 country.
China1 site
first hospital affiliated of Fujian medical university
Fuzhou, Fujian, 350005
About this study
Official title: Development of a Machine Learning-Based Nomogram for Predicting HIF-2α Expression Levels in Clear Cell Renal Cell Carcinoma
This project aims to conduct a multicenter retrospective study to collect clinical, CT imaging, and pathological data from patients. A comprehensive data management system will be established, and radiomic features will be extracted to integrate and analyze multicenter data. We will develop a predictive model based on CT radiomic features and perform both internal and external cohort validation. The model will predict HIF-2α expression levels and clinically relevant prognostic factors in ccRCC, enabling precise identification of patient populations responsive to the HIF-2α antagonist Belzutifan, thereby facilitating personalized treatment decisions, minimizing unnecessary therapeutic risks, and ultimately improving patient quality of life and clinical outcomes.
- Conditions
- Renal Clear Cell Carcinoma, HIF-2α, Radiomics, Nomogram
- Keywords
- Nomogram, Radiomics, HIF-2α, Renal clear cell carcinoma
- Medical subject headings
- Carcinoma, Renal Cell
What is being measured
The primary outcome is the main question the study is designed to answer.
HIF-2α Expression Levels in Clear Cell Renal Cell Carcinoma
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start1 Aug 2024
- Primary completion1 Sep 2026 (estimated)
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal Clear Cell CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- First Affiliated Hospital of Fujian Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07332923
- Sponsor's protocol ID
- MRCTA,ECFAH OfFMUI2024]639
- Status last verified
- Dec 2025
- First submitted
- 31 Dec 2025
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of a Machine Learning-Based Nomogram for Predicting HIF-2α Expression Levels in Clear Cell Renal Cell Carcinoma
- ClinicalTrials.gov ID
- NCT07332923
- Acronym / sponsor ID
- MRCTA,ECFAH OfFMUI2024]639
- Conditions
- Renal Clear Cell Carcinoma, HIF-2α, Radiomics, Nomogram
- Keywords
- Nomogram, Radiomics, HIF-2α, Renal clear cell carcinoma
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- First Affiliated Hospital of Fujian Medical UniversityUniversity, hospital or other
- Study start
- 1 Aug 2024 (actual)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 1 Sep 2026 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project aims to conduct a multicenter retrospective study to collect clinical, CT imaging, and pathological data from patients. A comprehensive data management system will be established, and radiomic features will be extracted to integrate and analyze multicenter data. We will develop a predictive model based on CT radiomic features and perform both internal and external cohort validation. The model will predict HIF-2α expression levels and clinically relevant prognostic factors in ccRCC, enabling precise identification of patient populations responsive to the HIF-2α antagonist Belzutifan, thereby facilitating personalized treatment decisions, minimizing unnecessary therapeutic risks, and ultimately improving patient quality of life and clinical outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with histologically confirmed renal cell carcinoma
Key inclusion criteria (5 listed)
- Pathologically confirmed clear cell renal cell carcinoma (ccRCC)
- Availability of comprehensive clinical, pathological, and follow-up information
- Access to preoperative non-contrast and contrast-enhanced CT images through the PACS database
- Adequately preserved pathological slides for subsequent immunohistochemical (IHC) or tissue microarray analysis
- Minimum of one post-treatment follow-up with documented treatment response or efficacy evaluation
Key exclusion criteria (4 listed)
- Patients considered ineligible for treatment owing to severe comorbid conditions or inability to undergo any therapeutic intervention
- Patients with concurrent malignancies, including prior treatment for other cancers or presence of untreated active malignancies
- Patients with inadequate CT image quality or missing imaging data
- Patients with missing or incomplete clinical, pathological, or follow-up information
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
HIF-2α Expression Levels in Clear Cell Renal Cell Carcinoma
Time frame: 1 week
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Renal Clear Cell Carcinoma
RecruitingPhase 3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Active, not recruitingPhase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Enrolling by invitation
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
Adenocarcinoma, Prostate Neoplasms
Not yet recruitingPhase 2
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
Locally Advanced Clear Cell Renal Cell Carcinoma
RecruitingObservational study
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Solid Tumor, Adult, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Renal Clear Cell Carcinoma and HIF-2α, run by First Affiliated Hospital of Fujian Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HIF-2α Expression Levels in Clear Cell Renal Cell Carcinoma (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.